Safety profile of efgartigimod from global clinical trials across multiple immunoglobulin G-mediated autoimmune diseases
Across clinical trials in IgG-mediated autoimmune diseases, efgartigimod was well tolerated with similar safety profiles regardless of dosing regimen.
Authors
- Adrian C. Newland (ORCID: https://orcid.org/0000-0003-1079-9496)
- René Kerstens (ORCID: https://orcid.org/0000-0001-6022-109X)
- Peter Ulrichts
- Catherine M. Broome (ORCID: https://orcid.org/0000-0003-1507-2851)
- Kelly Gwathmey (ORCID: https://orcid.org/0000-0002-7589-8826)
- James F. Howard (ORCID: https://orcid.org/0000-0002-7136-8617)
- Jon Beauchamp
- Jeffrey T. Guptill (ORCID: https://orcid.org/0000-0002-0312-0716)
- Sophie Steeland
- Jana Podhorna
- Zsuzsanna Bata‐Csörgõ (ORCID: https://orcid.org/0000-0002-3732-1743)
- Matthias Goebeler (ORCID: https://orcid.org/0000-0001-7095-9848)
- Hiroyuki Murai (ORCID: https://orcid.org/0000-0003-1612-1440)
- Jeffrey A. Allen (ORCID: https://orcid.org/0000-0001-8753-2680)
- Luc Truyen
- Yoshitaka Miyakawa (ORCID: https://orcid.org/0000-0002-4429-7227)
Institutions
- University of North Carolina at Chapel Hill (US)
- Queen Mary University of London (GB)
- Duke University (US)
- Georgetown University (US)
- Virginia Commonwealth University (US)
- University of Szeged (HU)
- University of Minnesota System (US)
- Universitätsklinikum Würzburg (DE)
- Argenx (Belgium) (BE)
- International University of Health and Welfare (JP)
- Saitama Medical University (JP)
Publication Details
- Journal
- Expert Review of Clinical Immunology
- Published
- 2025-04-29
- DOI
- https://doi.org/10.1080/1744666x.2025.2497840
- Citations
- 9
- Primary Topic
- Autoimmune Bullous Skin Diseases
- Type
- article
- Field-Weighted Citation Impact
- 13.24
Funders
- Argenx